Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	15.21B
Revenue (ttm)	844.86M
Net Income (ttm)	254.33M
Shares Out	81.56M
EPS (ttm)	3.15
PE Ratio	59.30
Forward PE	n/a
Dividend	5.45 (3.14%)
Ex-Dividend Date	May 29, 2024

Volume	256,239
Average Volume	325,643
Open	176.00
Previous Close	175.00
Day's Range	174.00 - 176.50
52-Week Range	166.00 - 215.00
Beta	0.34
RSI	70.20
Earnings Date	Mar 28, 2025

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2023, TPEX:6712's revenue was 758.39 million, an increase of 20.86% compared to the previous year's 627.51 million. Earnings were 539.40 million, an increase of 168.74%.